INSIGHTS ON PHARMACEUTICAL LOGISTICS

• Addressing The Acetonitrile Supply By Implementing Strategies

  Rising acetonitrile demand threatens supply chains; recovery and reuse methods using evaporation and crystallization produce high‑purity solvent, reducing costs, waste, and reliance on fresh supply.

• The Importance Of Quality In Raw Material Selection

  Learn how to select high-quality raw materials for cell-based manufacturing in this exploration of the criticality of raw materials, from preclinical development to commercialization. 

• Shedding Light On Photo-Stability Forced Degradation

  Ensure the stability and safety of your drug products by utilizing comprehensive forced degradation and photo-stability testing, guided by ICH and FDA standards, to identify degradation pathways and assess light exposure risks.

• The Crucial Role Of Cleaning In Effective VPHP Decontamination For Isolators

  Effective isolator cleaning is crucial for vapor phase hydrogen peroxide (VPHP) decontamination. Proper tools, techniques, and training ensure sterility, and regulatory compliance.

• Risk Mitigation For Late-Stage Clinical Assets

  6/11/2025

  Leveraging the competence and capabilities of the CDMO to bring forth innovative, flexible solutions to safeguard supply chains for their clients and, ultimately, for patients is crucial to strategic partnering.

• Site Transfer Of Tablet Production From Ex-U.S. To Georgia Site

  6/11/2025

  Explore how strategic U.S.-based manufacturing and supply chain diversification can reduce risk, lower costs, and enhance supply reliability for pharmaceutical products.

• The Way Forward: Supply Chain Solutions

  10/24/2024

  Learn how to build a resilient supply chain to navigate today's complex environment. Expert speakers share insights on optimization, innovation, and strategic planning to meet evolving market conditions.

• How To Select The Right Fill-Finish CDMO For Phase I–II

  3/16/2026

  Early‑phase programs require flexible, technically aligned fill‑finish partners. Mid‑sized CDMOs offer a balance of agility, infrastructure, and regulatory maturity suited to Phase I–II needs.

• Friendshoring: A Strategic Shift In Pharma Supply Chains

  4/11/2025

  To safeguard the consistent delivery of essential therapies to patients around the world, biopharmaceutical companies, alongside their CDMO partners, are rethinking traditional supply models.